Overview of Efficacy of Lorlatinib in the Treatment of ALK+ NSCLC

Opinion
Video

Dr. Kim provides an overview of the clinical evidence supporting lorlatinib as a first-line therapy for ALK+ metastatic NSCLC, focusing on the key efficacy outcomes from the phase 3 CROWN trial.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

  1. Dr.Thawani asks Dr. Kim: Can you provide an overview of the clinical evidence supporting lorlatinib as a first-line therapy for ALK+ metastatic NSCLC?
  • What were the key efficacy outcomes from the phase 3 CROWN trial?
Recent Videos
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
6 experts are featured in this series.
Related Content
Intricacies of EGFR-Mutated NSCLC Care From the Patient Perspective

Intricacies of EGFR-Mutated NSCLC Care From the Patient Perspective

ONCOLOGY Staff
February 8th 2025
Article

Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Updated Results Show THIO/Cemiplimab Improves Median OS in Advanced NSCLC

Updated Results Show THIO/Cemiplimab Improves Median OS in Advanced NSCLC

Tim Cortese
February 5th 2025
Article

6-thio-2’-deoxyguanosine sequenced plus cemiplimab elicited an OS of 16.9 months in the third-line setting for patients with advanced non–small cell lung cancer.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Zipalertinib Meets Primary ORR End Point in EGFR exon 20 NSCLC

Zipalertinib Meets Primary ORR End Point in EGFR exon 20 NSCLC

Tim Cortese
January 29th 2025
Article

Full results from the phase 1/2 REZILIENT1 trial evaluating zipalertinib in NSCLC will be shared at a future medical conference.

Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.

Enhanced Postoperative Recovery May Improve Outcomes in Elderly NSCLC

Roman Fabbricatore
January 28th 2025
Article

Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.